Elisa Cerri
About
Elisa Cerri is a scholar working on Oncology, Molecular Biology and Genetics.
According to data from OpenAlex, Elisa Cerri has authored 35 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Molecular Biology and 15 papers in Genetics. Recurrent topics in Elisa Cerri's work include Chronic Lymphocytic Leukemia Research (15 papers), Retinal Development and Disorders (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Elisa Cerri is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Retinal Development and Disorders (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Elisa Cerri collaborates with scholars based in United States, Italy and Australia. Elisa Cerri's co-authors include Andrew W. Roberts, Matthew S. Davids, John F. Seymour, Sari H. Enschede, John F. Gerecitano, William G. Wierda, Rod Humerickhouse, Lori A. Gressick, Monali Desai and Mary Ann Anderson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Elisa Cerri
34 papers receiving 2.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Elisa Cerri United States | 19 | 1.1k | 844 | 823 | 780 | 505 | 35 | 2.4k | ||
| Richard C. Frank United States | 21 | 236 0.2× | 1.1k 1.3× | 616 0.7× | 986 1.3× | 504 1.0× | 50 | 2.4k | ||
| Renee C. Tschumper United States | 31 | 1.7k 1.5× | 1.0k 1.2× | 1.3k 1.5× | 400 0.5× | 531 1.1× | 82 | 3.1k | ||
| Antonina V. Kurtova United States | 14 | 647 0.6× | 1.2k 1.4× | 466 0.6× | 1.0k 1.3× | 179 0.4× | 20 | 2.6k | ||
| Boris K. Lin United States | 26 | 543 0.5× | 2.8k 3.3× | 505 0.6× | 1.6k 2.0× | 2.4k 4.7× | 50 | 4.4k | ||
| J. Blake Bartlett United Kingdom | 20 | 560 0.5× | 1.6k 1.9× | 522 0.6× | 1.2k 1.5× | 1.7k 3.3× | 46 | 3.0k | ||
| Katja Zirlik Germany | 25 | 894 0.8× | 1.1k 1.3× | 707 0.9× | 581 0.7× | 437 0.9× | 45 | 2.4k | ||
| Maria Teresa Sabrina Bertilaccio Italy | 25 | 632 0.6× | 550 0.7× | 339 0.4× | 430 0.6× | 208 0.4× | 51 | 1.7k | ||
| Kurt Grünewald Austria | 18 | 282 0.2× | 902 1.1× | 180 0.2× | 669 0.9× | 342 0.7× | 29 | 2.2k | ||
| William Y. Go United States | 21 | 204 0.2× | 952 1.1× | 1.1k 1.3× | 2.6k 3.3× | 83 0.2× | 67 | 3.6k | ||
| Nathalie A. Lokker United States | 20 | 328 0.3× | 1.1k 1.3× | 108 0.1× | 468 0.6× | 476 0.9× | 29 | 2.1k |
Countries citing papers authored by Elisa Cerri
Since
Specialization
Citations
This map shows the geographic impact of Elisa Cerri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Cerri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Cerri more than expected).
Fields of papers citing papers by Elisa Cerri
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Elisa Cerri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Cerri. The network helps show where Elisa Cerri may publish in the future.
Co-authorship network of co-authors of Elisa Cerri
This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Cerri. A scholar is included among the top collaborators of Elisa Cerri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Cerri. Elisa Cerri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sagona, Giulia, Raffaele Mazziotti, Leonardo Lupori, et al.. (2020). Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency. Scientific Reports. 10(1). 18361–18361.
2.
Davids, Matthew S., Michael Hallek, William G. Wierda, et al.. (2018). Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. 24(18). 4371–4379.
3.
Criscuolo, Chiara, et al.. (2018). The retina as a window to early dysfunctions of Alzheimer's disease following studies with a 5xFAD mouse model. Neurobiology of Aging. 67. 181–188.
4.
Barzago, Maria Monica, Mami Kurosaki, Maddalena Fratelli, et al.. (2017). Generation of a new mouse model of glaucoma characterized by reduced expression of the AP-2β and AP-2δ proteins. Scientific Reports. 7(1). 11140–11140.
5.
Cerri, Elisa, et al.. (2017). Visual Evoked Potentials in Glaucoma and Alzheimer’s Disease. Methods in molecular biology. 1695. 69–80.
6.
Criscuolo, Chiara, et al.. (2017). Synaptic Dysfunction in Alzheimer’s Disease and Glaucoma: From Common Degenerative Mechanisms Toward Neuroprotection. Frontiers in Cellular Neuroscience. 11. 53–53.
7.
Roberts, Andrew W., Matthew S. Davids, John M. Pagel, et al.. (2015). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374(4). 311–322.
8.
Domenici, Luciano, Nicola Origlia, Benedetto Falsini, et al.. (2014). Rescue of Retinal Function by BDNF in a Mouse Model of Glaucoma. PLoS ONE. 9(12). e115579–e115579.
9.
Ma, Shuo, John F. Seymour, Mark C. Lanasa, et al.. (2014). ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.. Journal of Clinical Oncology. 32(15_suppl). 7013–7013.
10.
Seymour, John F., Matthew S. Davids, John M. Pagel, et al.. (2013). Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). 7018–7018.
11.
Seymour, John F., Matthew S. Davids, Mary Ann Anderson, et al.. (2012). The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. Blood. 120(21). 3923–3923.
12.
Davids, Matthew S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2012). The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. Blood. 120(21). 304–304.
13.
Glubb, Dylan M., Elisa Cerri, Wei Zhang, et al.. (2011). Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. Clinical Cancer Research. 17(16). 5257–5267.
14.
Allegrini, Giacomo, Alfredo Falcone, Antonio Fioravanti, et al.. (2008). A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. British Journal of Cancer. 98(8). 1312–1319.
15.
Cerri, Elisa, Alfredo Falcone, & Federico Innocenti. (2007). Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?. 5(2). 87–101.
16.
Graziani, Filippo, et al.. (2006). Association Between Osteonecrosis of the Jaws and Chronic High-Dosage Intravenous Bisphosphonates Therapy. Journal of Craniofacial Surgery. 17(5). 876–879.
17.
Masi, Gianluca, Lorenzo Marcucci, Fotios Loupakis, et al.. (2006). First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Annals of Oncology. 17(8). 1249–1254.
18.
Masi, Gianluca, Samanta Cupini, Lorenzo Marcucci, et al.. (2005). Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer. Annals of Surgical Oncology. 13(1). 58–65.
19.
Masi, Gianluca, Giacomo Allegrini, Samanta Cupini, et al.. (2004). First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Annals of Oncology. 15(12). 1766–1772.
20.
Falcone, Alfredo, Gianluca Masi, Samanta Cupini, et al.. (2004). Surgical resection of metastases (mts) after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 22(14_suppl). 3553–3553.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Richard C. Frank Breakdown of academic impact, for papers by Renee C. Tschumper Breakdown of academic impact, for papers by Antonina V. Kurtova Breakdown of academic impact, for papers by Boris K. Lin Breakdown of academic impact, for papers by J. Blake Bartlett Breakdown of academic impact, for papers by Katja Zirlik Breakdown of academic impact, for papers by Maria Teresa Sabrina Bertilaccio Breakdown of academic impact, for papers by Kurt Grünewald Breakdown of academic impact, for papers by William Y. Go Breakdown of academic impact, for papers by Nathalie A. Lokker